Otis Brawley leaves the American Cancer Society as it pursues “open-for-business” strategy amid sliding revenues November 09, 2018Vol.44 No.42By Paul Goldberg
Conversation with The Cancer LetterFree Waksal: Reflecting on the Tree of Life shooting and new American anti-Semitism November 02, 2018Vol.44 No.41By Paul Goldberg
Free Experts: Minimally invasive procedures in gynecology gained universal acceptance before hard questions were asked November 02, 2018Vol.44 No.41
Free Minimally invasive surgery lowers survival in cervical cancer, new studies show November 02, 2018Vol.44 No.41By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Ramirez: We no longer offer minimally invasive radical hysterectomy at MD Anderson November 02, 2018Vol.44 No.41By Matthew Bin Han Ong
Conversation with The Cancer LetterFree SGO’s Kesterson: Future studies are needed to define role of minimally invasive surgery in cervical cancer November 02, 2018Vol.44 No.41By Matthew Bin Han Ong
Trump’s drug pricing plan pegs Medicare Part B payments to international levels October 26, 2018Vol.44 No.40By Paul Goldberg
Has Tecentriq earned a role in treatment of triple-negative breast cancer?Here is what experts say October 26, 2018Vol.44 No.40
Conversation with The Cancer Letter NCI’s Korde: Follow-up needed to validate PFS with mature OS results for Tecentriq October 26, 2018Vol.44 No.40By Matthew Bin Han Ong
Long-awaited trial of checkpoint inhibitor in breast cancerproduces 2-month PFS gain; no final OS advantage seen—yet October 26, 2018Vol.44 No.40By Matthew Bin Han Ong
